| 前收市價 | 250.79 |
| 開市 | 243.40 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 235.77 - 247.55 |
| 52 週波幅 | 235.77 - 323.78 |
| 成交量 | |
| 平均成交量 | 10,353 |
| 市值 | 196.279B |
| Beta 值 (5 年，每月) | 0.15 |
| 市盈率 (最近 12 個月) | 15.38 |
| 每股盈利 (最近 12 個月) | 15.70 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 10.86 (4.50%) |
| 除息日 | 2024年3月14日 |
| 1 年預測目標價 | 無 |
ZacksRoche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
- Reuters
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
Roche confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter sales slipped by 6% on the loss on COVID-19-related revenue. Quarterly sales fell to 14.4 billion Swiss francs ($15.80 billion), the family-controlled drugmaker said in a statement on Wednesday, hurt also by a strong Swiss franc that weighed on overseas revenue but in line with analysts expectations. Roche, which does not disclose quarterly earnings, said the rest of the year would no longer be burdened by year-earlier comparisons that were inflated by COVID-related sales.
ZacksRoche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
